— Report will be subject of CTAF meeting in May 2021; Open Input now being accepted until October 16, 2020 —
BOSTON, September 29, 2020 – The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of aducanumab (Biogen) for treatment of Alzheimer’s disease. An FDA decision on aducanumab is expected in early 2021.
The assessment will be publicly discussed during a meeting of the California Technology Assessment Forum (CTAF) in May 2021, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s report.
ICER’s website provides timelines of key posting dates and public comment periods for this assessment. An Open Input period begins today and is intended to allow stakeholders to share key information relevant to the development of the evidence report. Comments will be accepted from all interested stakeholders until October 16, 2020 at 5 p.m. ET. During this time, ICER will contact key patient groups and clinical experts to gain further insights on the patient perspective and clinical context of treating Alzheimer’s disease.
For more information about the Open Input period, visit ICER’s website. ICER’s Manufacturer Engagement Guide, Patient Participation Guide, and Patient Guide to Open Input provide additional information for manufacturers and patient groups, including an explanation of what types of information may be most informative. There are no page limits to Open Input submissions, and input received will be incorporated throughout report development. All input can be emailed to firstname.lastname@example.org and must be received by 5 p.m. ET on October 16, 2020 to be considered.
A draft scoping document, which will provide more detail on ICER’s planned analysis, will be available on October 21, 2020. That document will be open to public comment for three weeks.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.